About 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha
1-acyl-sn-glycerol-3-phosphate acyltransferase alpha (AGPAT1) is a protein
from Homo sapiens identified by UniProt accession
Q99943, 283 residues long.
MolForge cross-references it against 0 known binders and
199 disease associations.
Target properties
| Protein name | 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha |
|---|
| UniProt accession | Q99943 |
|---|
| Gene | AGPAT1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 283 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (199)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.18
- breast adenocarcinoma · score 0.18
- alcohol consumption measurement · score 0.13
- waist circumference · score 0.09
- risk-taking behaviour · score 0.08
- pulse pressure measurement · score 0.07
- ulcerative colitis · score 0.06
- phospholipid measurement · score 0.06
- 46,XX gonadal dysgenesis · score 0.05
- infection · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q99943-F1 | alphafold | PREDICTED | 90.77 | — |
Amino-acid sequence (283 residues)
MDLWPGAWML LLLLFLLLLF LLPTLWFCSP SAKYFFKMAF YNGWILFLAV LAIPVCAVRG RNVENMKILR LMLLHIKYLY GIRVEVRGAH HFPPSQPYVV VSNHQSSLDL LGMMEVLPGR CVPIAKRELL WAGSAGLACW LAGVIFIDRK RTGDAISVMS EVAQTLLTQD VRVWVFPEGT RNHNGSMLPF KRGAFHLAVQ AQVPIVPIVM SSYQDFYCKK ERRFTSGQCQ VRVLPPVPTE GLTPDDVPAL ADRVRHSMLT VFREISTDGR GGGDYLKKPG GGG
Explore 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets